John Wilkinson


It is great to be able to put my technical background into assisting clients with developing their businesses.

John Wilkinson's practice focuses primarily on the life sciences sector, advising pharmaceutical, biotechnology and medical technology companies on a wide range of IP, regulatory, antitrust and transactional matters. Amongst other things, John's practice has involved a number of highly complex alliances and joint ventures, co-promotional and co-marketing arrangements, distribution and supply agreements, together with the operational, IP, antitrust and regulatory issues relating to such transactions.

Download full bio 


  • Bavarian Nordic Acquires Emergent BioSolutions’ Travel Vaccines Portfolio 

  • Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million 

  • Silence Therapeutics Enters Collaboration With Mallinckrodt Worth up to $2 Billion 

  • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 

  • Mission Therapeutics Enters Collaboration Agreement with AbbVie 

  • View all

"He is one of the pioneers of the biotech industry and is doing cutting-edge work." – Chambers & Partners, 2020

  • College of Law, Chester
    MAC, Law Society Finals

  • Imperial College London
    BS, Chemistry

Rankings & Accolades

    Legal 500 UK: Life Sciences and Healthcare (2022)

    Chambers & Partners UK: Transactional Life Sciences

    The Legal 500 UK: Transactional Life Sciences

    PLC Global Counsel: Transactional Life Sciences

    IAM's Guide to the World's Leading Patent & Technology Licensing Lawyers

    IAM Patent 1000

    IAM Strategy 300

    Who's Who Legal Life Sciences: Transactional - Global Leader (2020) and Transactional Life Sciences Lawyer of the Year (2016)

    The Times: Lawyer of the Week